Immunotherapy combo offers new hope for Hard-to-Treat cancers
Disease control
Recruiting now
This study is for people with certain cancers (like lymphoma, breast, lung, or liver cancer) that have returned or not improved with standard treatment. Researchers are testing an immunotherapy drug (anti-PD-1 antibody) alone or combined with a low-dose chemotherapy-like drug (de…
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC